Ionis: FDA Approves Rare-Disease Drug Tryngolza; Shares Undervalued for Long-Term Investors

Ionis Pharmaceuticals received approval from the US Food and Drug Administration for Tryngolza (pipeline candidate olezarsen). This is the first treatment approved for adults with familial chylomicronemia syndrome, a rare genetic disorder that leads to dangerously high triglyceride levels, risking life-threatening pancreatitis and other complications. We are maintaining our fair value estimate of $69 per share, and we view shares as very undervalued, currently trading in 5-star territory at an attractive entry point for long-term investors with a high degree of risk tolerance.